Analyst Overvalued Stocks on the TSX July 2025

July 29, 2025

Analyst Overvalued

Companies on this list are considered overvalued based on the analyst consensus. This means that the average analyst target price is less than the close price.

TSX Venture Exchange

The TSX Venture Exchange is a stock exchange headquartered in Calgary, Alberta, Canada. It is an exchange for the securities of early-stage businesses.

About the Data

This table includes the close price and analyst target price mean from most recent available data. The fiscal year indicates the year for the analyst target price, as the target may not always be for the current year. The number of estimates indicates the number of analyst targets used to calculate the target price mean.

How do you use this table?

Analysts believe that the companies on this list will see the close price drop to their target price mean by the target year indicated. Companies with a large analyst following or large difference between close price and target price are particularly interesting to investigate further. This becomes a starting point for further analysis to understand why these companies are overvalued. Stocks in this category are generally sold to preserve capital.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose PriceTarget Price MeanTarget YearNumber of EstimatesCurrency
SXGC Southern Cross Gold Consolidated Ltd 5.55 5.13 2026 3 CAD
NGEN NervGen Pharma Corp 5.15 4.50 2025 1 CAD
All data provided as at market close May 29, 2025.

Company Details

Southern Cross Gold Consolidated Ltd

SXGC:TSX-V

Close Price

5.55

Target Price Mean

5.13

Target Year

2026

Target Price # Estimates

3

Southern Cross Gold Consolidated Ltd is a gold exploration company. The projects of the company include Sunday Creek, Redcastle, MT Isa, and others. The Company is also engaged exploring in antimony in the Victorian Goldfields.

Access the stockcalc valuation


NervGen Pharma Corp

NGEN:TSX-V

Close Price

5.15

Target Price Mean

4.50

Target Year

2025

Target Price # Estimates

1

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Access the stockcalc valuation


Southern Cross Gold and NervGen Pharma are among the most overvalued TSX stocks this month. See the most overvalued companies on the blog: https://www.stockcalc.com/Blog/analyst-overvalued-stocks-tsx-july-2025
Southern Cross Gold $SXGC and NervGen Pharma $NGEN on the #TSX among the most overvalued this month. See the full list of overvalued companies: https://www.stockcalc.com/Blog/analyst-overvalued-stocks-tsx-july-2025
Southern Cross Gold and NervGen Pharma are among the most overvalued TSX stocks this month. See the most overvalued companies on the blog: https://www.stockcalc.com/Blog/analyst-overvalued-stocks-tsx-july-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.